Fabrication of gastro-floating sustained-release etoricoxib and famotidine tablets : design, optimization, in-vitro, and in-vivo evaluation
In this study, a new gastro-floating sustained-release tablet (GFT) with a combination of Etoricoxib (ET) and Famotidine (FM) was successfully developed. GFTs were prepared by using a combination of hydrophilic swellable natural/semi-synthetic polymers as a controlled-release layer. Through a 24 full factorial statistical experimental design, the effects of formulation factors on the release of GFTs were conducted. The ideal floating tablet (FT) comprised konjac-gum (150 mg), guar-gum (26.57 mg), xanthan-gum (54.17 mg), and HPMC-K15-M (69.25 mg). The ideal FT exhibited a high swelling index (SI) (297.7%) and rapid FLT (around 50 s) in 0.1 N HCl as well as controlled release of ET (22.43% in 1 h and 77.47% in 8 h) and FM (24.89% in 1 h and 93.82% in 8 h) with the absence of any drug-excipient interactions. The AUC0∼72 (ng h/mL) of ET and FM in the GFTs were approximately double-fold of the market, respectively. The relative bioavailability was (207.48 ± 12.02% and 208.51 ± 13.11%) compared with commercial tablets. The X-ray imaging showed a promising buoyancy ability for approximately 8 h. These findings revealed the successful preparation of the sustained-release floating tablet with improved dual drug delivery.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Pharmaceutical development and technology - (2024) vom: 22. Apr., Seite 1-16 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Saady, Marwa [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Bioavailability |
|---|
| Anmerkungen: |
Date Revised 22.04.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1080/10837450.2024.2343320 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM37096621X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM37096621X | ||
| 003 | DE-627 | ||
| 005 | 20240422232434.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240412s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/10837450.2024.2343320 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1383.xml |
| 035 | |a (DE-627)NLM37096621X | ||
| 035 | |a (NLM)38607310 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Saady, Marwa |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Fabrication of gastro-floating sustained-release etoricoxib and famotidine tablets |b design, optimization, in-vitro, and in-vivo evaluation |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 22.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a In this study, a new gastro-floating sustained-release tablet (GFT) with a combination of Etoricoxib (ET) and Famotidine (FM) was successfully developed. GFTs were prepared by using a combination of hydrophilic swellable natural/semi-synthetic polymers as a controlled-release layer. Through a 24 full factorial statistical experimental design, the effects of formulation factors on the release of GFTs were conducted. The ideal floating tablet (FT) comprised konjac-gum (150 mg), guar-gum (26.57 mg), xanthan-gum (54.17 mg), and HPMC-K15-M (69.25 mg). The ideal FT exhibited a high swelling index (SI) (297.7%) and rapid FLT (around 50 s) in 0.1 N HCl as well as controlled release of ET (22.43% in 1 h and 77.47% in 8 h) and FM (24.89% in 1 h and 93.82% in 8 h) with the absence of any drug-excipient interactions. The AUC0∼72 (ng h/mL) of ET and FM in the GFTs were approximately double-fold of the market, respectively. The relative bioavailability was (207.48 ± 12.02% and 208.51 ± 13.11%) compared with commercial tablets. The X-ray imaging showed a promising buoyancy ability for approximately 8 h. These findings revealed the successful preparation of the sustained-release floating tablet with improved dual drug delivery | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Etoricoxib | |
| 650 | 4 | |a GRDDS | |
| 650 | 4 | |a bioavailability | |
| 650 | 4 | |a famotidine | |
| 650 | 4 | |a floating sustained-release | |
| 650 | 4 | |a x-ray imaging | |
| 700 | 1 | |a Shoman, Nabil A |e verfasserin |4 aut | |
| 700 | 1 | |a Teaima, Mahmoud |e verfasserin |4 aut | |
| 700 | 1 | |a Abdelmonem, Rehab |e verfasserin |4 aut | |
| 700 | 1 | |a El-Nabarawi, Mohamed A |e verfasserin |4 aut | |
| 700 | 1 | |a Elhabal, Sammar Fathy |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Pharmaceutical development and technology |d 1998 |g (2024) vom: 22. Apr., Seite 1-16 |w (DE-627)NLM094740194 |x 1097-9867 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:22 |g month:04 |g pages:1-16 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/10837450.2024.2343320 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 22 |c 04 |h 1-16 | ||